YU13502A - Derivati amino-triazolopiridina - Google Patents
Derivati amino-triazolopiridinaInfo
- Publication number
- YU13502A YU13502A YU13502A YUP13502A YU13502A YU 13502 A YU13502 A YU 13502A YU 13502 A YU13502 A YU 13502A YU P13502 A YUP13502 A YU P13502A YU 13502 A YU13502 A YU 13502A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- phenyl
- optionally substituted
- hydrogen
- compounds
- amino
- Prior art date
Links
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical class NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- -1 substituted Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Pronalazak se odnosi na jedinjenja formule I, naznacena time sto R1 perdstavlja 5-to ili 6-toclanu heteroarilnu grupu, koja sadrzi 1 do 3 heteroatoma, izabrana izmedju N, O ili S, i cije su grupe opciono supstituisane jednim ili sa dva supstituenta, koji su nizi alkil, -(CH2)nOH, halogen ili nizi alkoksi, i naznacena time sto heteroarilne grupe mogu biti opciono vezane za pirazolski prsten preko nekog alkilena ili alkenil grupe ili je to fenil, opciono supstituisan jednim ili sa dva supstituenta, koji su nizi alkil, hidroksi-nizi alkil, halogen, hidroksi ili nizi alkoksi ili je -O(CH2)nfenil, benzofuril, indolil ili benzotiofenil ili je -S-nizi alkil; R2 i R4 su nezavisno jedan od drugog, vodonik, cijano ili -S(O)2-fenil; R3 je vodonik, halogen ili 5-to ili 6-toclana heteroarilna grupa, koja sadrzi 1 do 3 heteroatoma, izabrana izmedju N, O ili S i gde su grupe opciono supstituisane jednim ili sa dva supstituenta, koji su nizi alkil, -(CH2)n-aril, hldroksi, halogen, nizi alkoksi, morfolinil, amino, nizi alkilamino ili -C(O)NR'2, naznaceno time sto je R* nizi alkil ili vodonik ili je fenil, opciono supstituisan jednim ili sa dva supstituenta koji su halogen, nizi alkoksi, amino, di-nizi alkil amino, CF3, -OCF3, -NHC(O)nizi alkil cijano, -C(O)-nizi alkil, -C(O)O-nizi alkil, -S-nizi alkil, -S(O)2NH-fenil, -S(O)2metilpiperazinil; ili je NR'R", naznacen time sto su R' i R", nezavisno jedan od drugog, vodonik, -(CH2)nfenil, koji je opciono supstituisan halogenom ili nizom alkoksi grupom, -CH(nizi alkil)-fenil, indan-1-il, 1,2,3,4-tetrahidro-naftalen ili cikloalkil; ili je O-fenil, ciji je fenilni prsten opciono supstituisan halogenom, nizom alkil ili nizom alkoksi grupom, -O-tetraidronaftalenil ili -O-CH2-6-metil-piridin-2-il; ili je -benzol[1,3]dioksolil, -1H-indol-5-il, naftil, benzofuran-2-il, 1,3,4,9-tetrahidro-b-karbolin-2-il, piperidin-1-il, pirolidin-1-il, piperazin-4-il-metil ili morfolinil; R5 je -NR2, pri cemu R moze ili ne mora biti vodonik, nizi alkil, fenil, benzil, -CO-nizi alkil, -CO-nizi alkoksi, -nizi alkenil, -CO(CH2)n-fenil ili -COO(CH2)n-fenil, naznacen time sto je fenilni prsten opciono supstituisan sa CF3 nizom alkoksi, halogen ili nizom alkil grupom, -CO(CH2)3-NHCO-nizi alkoksi, -(CH2)n-fenil, naznacen time, sto je fenilni prsten opciono supstituisan nizom alkoksi, CF3 ili halogenom ili je 4,5-dihidro-1H-imidazol-2-il-benzojeva kiselina, 1,4,5,6-tetrahidro-pirimidin-2-il-benzojeva kiselina ili 4,5,6,7-tetrahidro-1H-[1,3]diazepin-2-il-benzojeva kiselina; n je 0-4, i njihove farmaceutski prihvatljive soli.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99117578 | 1999-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU13502A true YU13502A (sh) | 2004-11-25 |
Family
ID=8238933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU13502A YU13502A (sh) | 1999-09-06 | 2000-08-28 | Derivati amino-triazolopiridina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6355653B1 (sh) |
| EP (1) | EP1214322A2 (sh) |
| JP (1) | JP2003528811A (sh) |
| KR (1) | KR20020027625A (sh) |
| CN (1) | CN1379777A (sh) |
| AR (1) | AR037484A1 (sh) |
| AU (1) | AU7511000A (sh) |
| BR (1) | BR0013792A (sh) |
| CA (1) | CA2383998A1 (sh) |
| CZ (1) | CZ20021220A3 (sh) |
| HR (1) | HRP20020172A2 (sh) |
| HU (1) | HUP0203316A3 (sh) |
| IL (1) | IL148167A0 (sh) |
| MA (1) | MA26816A1 (sh) |
| MX (1) | MXPA02001748A (sh) |
| NO (1) | NO20021077L (sh) |
| PE (1) | PE20010629A1 (sh) |
| PL (1) | PL354240A1 (sh) |
| TR (1) | TR200200579T2 (sh) |
| WO (1) | WO2001017999A2 (sh) |
| YU (1) | YU13502A (sh) |
| ZA (1) | ZA200201055B (sh) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506772B1 (en) | 2000-12-15 | 2003-01-14 | Hoffmann-La Roche Inc. | Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| US6693116B2 (en) | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| RU2296763C2 (ru) | 2001-10-08 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | Амид 8-амино-[1.2.4]триазоло-[1.5-а]пиридин-6-карбоновой кислоты и содержащее его лекарственное средство |
| US6875772B2 (en) | 2001-11-30 | 2005-04-05 | Schering Corporation | [1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| US20040198753A1 (en) | 2002-01-28 | 2004-10-07 | Hiroshi Kase | Methods of treating patients suffering from movement disorders |
| CA2489252A1 (en) * | 2002-06-13 | 2003-12-24 | Pfizer Inc. | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use |
| EP1711498A2 (en) * | 2004-01-26 | 2006-10-18 | Altana Pharma AG | 1,2,4-triazolo¬1,5-a|pyridines as gastric acid secretion inhibitors |
| JP2008524330A (ja) | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| US7935715B2 (en) * | 2006-07-28 | 2011-05-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| EA200900403A1 (ru) * | 2006-09-25 | 2009-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения, которые модулируют рецептор св2 |
| KR20090094336A (ko) * | 2006-11-27 | 2009-09-04 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유도체 |
| DE602007012133D1 (de) | 2006-12-01 | 2011-03-03 | Andrew Burritt | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| CA2682925A1 (en) * | 2007-04-10 | 2008-10-16 | David C. Ihle | Heteroaryl amide analogues |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009061652A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP2011520884A (ja) * | 2008-05-13 | 2011-07-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調するスルホン化合物 |
| EP2288260A4 (en) * | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| EP2296475A4 (en) | 2008-06-20 | 2014-03-05 | Genentech Inc | TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS |
| WO2010005782A1 (en) * | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| KR20110063438A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| MY153913A (en) * | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CA2763900A1 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
| HRP20140705T1 (hr) * | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| US8383651B2 (en) * | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2758396B1 (en) * | 2011-09-19 | 2017-03-29 | F. Hoffmann-La Roche AG | Triazolopyridine compounds as pde10a inhibitors |
| WO2013043520A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| BR112018068681A2 (pt) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas |
| CN106543175B (zh) * | 2016-10-28 | 2018-06-01 | 上海大学 | 三芳基[1,2,4]三氮唑[1,5-a]吡啶衍生物及其制备方法 |
| CN109963854B (zh) * | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| MA52422A (fr) | 2018-02-27 | 2021-01-06 | Incyte Corp | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MA53097A (fr) * | 2018-07-05 | 2021-05-12 | Incyte Corp | Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b |
| WO2020054712A1 (ja) * | 2018-09-12 | 2020-03-19 | 日本化薬株式会社 | 有害生物防除剤 |
| MA54551A (fr) | 2018-12-20 | 2021-10-27 | Incyte Corp | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP2024507022A (ja) * | 2021-01-09 | 2024-02-16 | バグワークス・リサーチ・インコーポレイテッド | アデノシン２Ａ受容体及びアデノシン２Ｂ受容体アンタゴニストとしてのジアミノピラゾロ［１，５－ａ］ピリミジン－６－カルボニトリル化合物 |
| CN116082335A (zh) * | 2023-01-16 | 2023-05-09 | 上海凌凯医药科技有限公司 | 一种二芳基醚化合物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226735D0 (en) | 1992-12-22 | 1993-02-17 | Ici Plc | Azole derivatives |
| WO1999043678A1 (en) | 1998-02-24 | 1999-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for parkinson's disease |
-
2000
- 2000-08-24 US US09/645,127 patent/US6355653B1/en not_active Expired - Fee Related
- 2000-08-28 HU HU0203316A patent/HUP0203316A3/hu unknown
- 2000-08-28 CA CA002383998A patent/CA2383998A1/en not_active Abandoned
- 2000-08-28 JP JP2001522222A patent/JP2003528811A/ja active Pending
- 2000-08-28 WO PCT/EP2000/008372 patent/WO2001017999A2/en not_active Ceased
- 2000-08-28 BR BR0013792-8A patent/BR0013792A/pt not_active IP Right Cessation
- 2000-08-28 PL PL00354240A patent/PL354240A1/xx not_active Application Discontinuation
- 2000-08-28 EP EP00964043A patent/EP1214322A2/en not_active Withdrawn
- 2000-08-28 CN CN00812501A patent/CN1379777A/zh active Pending
- 2000-08-28 MX MXPA02001748A patent/MXPA02001748A/es unknown
- 2000-08-28 HR HR20020172A patent/HRP20020172A2/hr not_active Application Discontinuation
- 2000-08-28 IL IL14816700A patent/IL148167A0/xx unknown
- 2000-08-28 YU YU13502A patent/YU13502A/sh unknown
- 2000-08-28 KR KR1020027002990A patent/KR20020027625A/ko not_active Ceased
- 2000-08-28 AU AU75110/00A patent/AU7511000A/en not_active Abandoned
- 2000-08-28 CZ CZ20021220A patent/CZ20021220A3/cs unknown
- 2000-08-28 TR TR2002/00579T patent/TR200200579T2/xx unknown
- 2000-09-04 AR ARP000104612A patent/AR037484A1/es not_active Application Discontinuation
- 2000-09-04 PE PE2000000903A patent/PE20010629A1/es not_active Application Discontinuation
-
2002
- 2002-02-06 ZA ZA200201055A patent/ZA200201055B/xx unknown
- 2002-03-05 NO NO20021077A patent/NO20021077L/no not_active Application Discontinuation
- 2002-03-06 MA MA26540A patent/MA26816A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20021077D0 (no) | 2002-03-05 |
| TR200200579T2 (tr) | 2002-12-23 |
| ZA200201055B (en) | 2003-07-30 |
| NO20021077L (no) | 2002-03-05 |
| MXPA02001748A (es) | 2002-08-06 |
| BR0013792A (pt) | 2002-05-14 |
| JP2003528811A (ja) | 2003-09-30 |
| CN1379777A (zh) | 2002-11-13 |
| KR20020027625A (ko) | 2002-04-13 |
| IL148167A0 (en) | 2002-09-12 |
| WO2001017999A3 (en) | 2001-12-06 |
| HUP0203316A3 (en) | 2004-07-28 |
| US6355653B1 (en) | 2002-03-12 |
| HUP0203316A2 (hu) | 2003-01-28 |
| EP1214322A2 (en) | 2002-06-19 |
| HRP20020172A2 (en) | 2003-10-31 |
| CZ20021220A3 (cs) | 2002-10-16 |
| MA26816A1 (fr) | 2004-12-20 |
| CA2383998A1 (en) | 2001-03-15 |
| PE20010629A1 (es) | 2001-05-30 |
| WO2001017999A2 (en) | 2001-03-15 |
| AU7511000A (en) | 2001-04-10 |
| PL354240A1 (en) | 2003-12-29 |
| AR037484A1 (es) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU13502A (sh) | Derivati amino-triazolopiridina | |
| ES2167371T3 (es) | Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos. | |
| BR0215202A (pt) | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso | |
| HUP9902340A2 (hu) | Kondenzált piridinek és pirimidinek aril-amino-származékai, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények, továbbá e vegyületek alkalmazása | |
| CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
| ATE217623T1 (de) | Azindolethylaminderivate als nikotin-acetylcholin-rezeptor bindung verbindungen | |
| ES8404990A1 (es) | Un procedimiento para la preparacion de derivados de prolina. | |
| DE69505968D1 (de) | Azolidindion-derivate und ihre anwendung als antihyperglykämika | |
| HUP9802552A2 (hu) | Piperazinszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CA2036618A1 (en) | Fused thiophene derivatives, their production and use | |
| ATE288895T1 (de) | Wachstumshormon-freisetzende oxindolderivate | |
| TW354787B (en) | 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents | |
| DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
| DE68925503D1 (de) | Pyridin-Verbindungen und ihre pharmazeutische Verwendung | |
| MXPA02004448A (es) | Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii. | |
| TW325462B (en) | Urea derivatives and the pharmaceutical composition for 5-HT antagonist | |
| EA200000023A1 (ru) | Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола | |
| DK0915894T3 (da) | Nukleotidanaloger | |
| CA2264065A1 (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists | |
| NO890440L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater. | |
| CA2437006A1 (en) | Aminotriazolopyridine derivatives as adenosine receptor ligands | |
| HUP0003962A2 (hu) | Kinuklidinil-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények, e vegyületek alkalmazása, valamint intermedierjeik | |
| ATE285771T1 (de) | Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung | |
| AR027035A1 (es) | Pirroles sustituidos | |
| FI922835A0 (fi) | Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi |